Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial

The University of Queensland, Shionogi, The Henderson Foundation, and the National Medical Research Council (Singapore).